a chemical conjugate of a monoclonal antibody to the serotonin transporter (SERT, Cat. #AB-N09)
and the ribosome-inactivating protein, saporin

(molecular weight 220 kDa)

Anti-SERT-SAP utilizes a monoclonal antibody to the fourth extracellular domain of the serotonin re-uptake transporter (SERT). SERT is the major determinant of serotonin inactivation following release at synapses, is the site of action for many tricyclic antidepressants and the SSRIs (serotonin-selective reuptake inhibitors), and is also targeted by a number of psychostimulants including cocaine, methylphenidate, and MDMA ‘ecstasy.’ SERT is produced from a single gene and is expressed in both the CNS and GI system. Decreased serotonergic neurotransmission has been proposed to play a key role in the etiology of depression. Recent findings suggest that SERT might be linked to both neurotic and sexual behavior as well as to obsessive-compulsive disorder (OCD).

Elimination of Specific Cell Type

• Specifically targets cells that express SERT in rat and human.
• All other cells are left untouched.

Effective Tool

• The serotonergic system is known to modulate mood, emotion, sleep and appetite and thus is implicated in the control of numerous behavioral and physiological functions.

Check out these articles in Targeting Trends for more information. Apr-May-Jun 2006 - Targeted Toxins in Pain, continued October 2002 - Featured Product: Anti-SERT-SAP